Index Entries

L. Maria Gutschi, David J. Speicher, Susan Natsheh, Phil Oldfield, Philip Britz-McKibbon, Michael Palmer, Neil Karrow, Bernard Massie, Bonnie Mallard, Glenn Chan, and Steven Pelech
October 29, 2022
Canadian Covid Care Alliance

“This article summarizes the main findings of a more detailed technical assessment concerning the development and manufacturing of the BioNTech/Pfizer’s COVID-19 quasi-vaccine BNT162b. A number of deficiencies in the product’s development were identified by regulatory agencies and appear to have either been ignored or glossed over...

The quasi-vaccine quality is questionable and variable. There may be substantial differences in the mRNA vaccines between batches and even between vials. This may be due to variations in handling, freezing/thawing/dilution requirements, the short half-life of the mRNA, and manufacturing variability…
 
It appears that there is insufficient evidence that this vaccine product meets the quality required of a pharmaceutical product, raising concerns about its safety and efficacy… Real-world data falsifies the original claim that mRNA based COVID-19 biologics function as an authentic vaccine for preventing viral infection and transmission rather than as a short-term gene-based therapeutic agent that might alleviate at best symptom severity. With this in mind, the authorization for these products should be suspended until the concerns in this review have been resolved and publicly verified by the regulatory authorities.”

document
COVID-19,FDA approvals,manufacturers,vaccine composition,vaccine dynamics,vaccine ingredients,vaccine quality control,vaccines